Tonix names Thomas Englese its first chief commercial officer
BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) promoted Thomas Englese to chief commercial officer, effective immediately, in an announcement dated Sept. 8, 2026. CEO Seth Lederman calls it the company's first CCO appointment. Englese had held the title of executive vice president, commercial operations, since September 2024, which works out to two years.
Englese keeps three marketed products across two indications
He continues to direct sales, marketing, market access and commercial operations for three products. TONMYA (cyclobenzaprine HCl sublingual tablets) is for fibromyalgia in adults. Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) are both for acute migraine in adults.
The release describes no change in scope. What changes is the title: the commercial organization for all three products now sits under a named C-suite officer.